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A B S T R A C T
Galactooligosaccharides (GOS) are prebiotic compounds synthesized from lactose using bacterial enzymes and
are known to stimulate growth of beneﬁcial biﬁdobacteria in the human colon. Bacteroides thetaiotaomicron is a
prominent human colon commensal bacterial species that hydrolyzes GOS using an extracellular Glycosyl
Hydrolase (GH) family GH53 endo-galactanase enzyme (BTGH53), releasing galactose-based products for
growth. Here we dissect the molecular basis for GOS activity of this B. thetaiotaomicron GH53 endo-galactanase.
Elucidation of its X-ray crystal structure revealed that BTGH53 has a relatively open active site cleft which was
not observed with the bacterial enzyme from Bacillus licheniformis (BLGAL). BTGH53 acted on GOS with degree
of polymerization ≤3 and therefore more closely resembles activity of fungal GH53 enzymes (e.g. Aspergillus
aculeatus AAGAL and Meripileus giganteus MGGAL). Probiotic lactobacilli that lack galactan utilization systems
constitute a group of bacteria with relevance for a healthy (infant) gut. The strains tested were unable to use
GOS≥DP3. However, they completely consumed GOS in the presence of BTGH53, resulting in clear stimulation
of their extent of growth. The extracellular BTGH53 enzyme thus may play an important role in carbohydrate
metabolism in complex microbial environments such as the human colon. It also may ﬁnd application for the
development of synergistic synbiotics.
1. Introduction
The human gut is colonized by trillions of bacteria which are col-
lectively called the human gut microbiota. Gut bacteria have tre-
mendous impact on our health and enable humans to degrade most of
the food we ingest. In particular bacteria that colonize the human colon
are highly specialized in harvesting energy from complex carbohy-
drates, such as those found in plant material, in complex human glycans
and in fungal and bacterial carbohydrates (Ndeh and Gilbert, 2018). To
acquire energy from carbohydrates in such extremely competitive en-
vironments, bacteria express speciﬁc enzymes and transporters to target
and degrade these carbohydrate substrates. The presence of particular
carbohydrates therefore may largely dictate which bacteria will grow
and persist in the colon. This may allow us to nurture our colonic
bacteria by eating a diet full of complex carbohydrates or by ingesting
functional carbohydrates as food supplements, such as prebiotics
(Fuller and Gibson, 1997).
A prebiotic is generally deﬁned as a “substrate that is selectively
utilized by host microorganisms conferring a health beneﬁt” (Gibson
et al., 2017). People may ingest prebiotics as a way to promote the
growth of healthy gut bacteria in times of intestinal distress, e.g. during
antibiotic treatment, infant colic, inﬂammatory bowel disease or col-
orectal cancer (Macfarlane et al., 2007). Galactooligosaccharides (GOS)
represent one class of prebiotics synthesized from lactose comprising
often glucose at the reducing end and a galactose-chain with a degree of
polymerization varying from 2 to 6, constituting a mixture of non-
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digestible carbohydrates based on galactose. GOS are most commonly
used in infant formula. Their application in infant formula dates back to
the discovery of the stimulatory eﬀect of human milk on colonic bac-
teria in the last century. Initially, the growth of a prominent infant gut
bacterium, Lactobacillus biﬁdus (now known as Biﬁdobacterium biﬁdum),
was linked to milk from breastfeeding mothers (Gauhe et al., 1954;
György et al., 1954a,b,c; Norris et al., 1950; Rose et al., 1954). Later it
was found to be based on consumption of human milk oligosaccharides,
or HMOs (György et al., 1974; György and Rose, 1955). HMOs thus
became known as the “biﬁdus factor” and since then, much research has
gone into determining the structures of HMOs (of which there are over
200) and into ﬁnding compounds and molecules that mimic the biﬁdus
eﬀect (Polonovski and Montreuil, 1954; Yazawa and Tamura, 1982). In
the late 20th century it was shown that enzymatically synthesized GOS
are biﬁdogenic and, similar to HMOs, stimulate the growth of biﬁdo-
bacteria (Ito et al., 1990; Smart, 1991). HMOs are complex structures
and expensive and laborious to synthesize, while GOS are relatively
easy to produce at industrial scale and have similar eﬀects on growth of
infant colonic microbiota (Bode, 2012; Ito et al., 1993). From the early
2000’s onwards the infant nutrition industry started to use GOS to
produce an infant formula that mimics the more natural eﬀects of
mother’s milk (Otieno, 2010).
With the increasing awareness of how strongly the human colonic
microbiome is linked to our overall well-being, researchers and food
nutritionists alike aim to build up and maintain a healthy and balanced
colonic microbiome (Sanders et al., 2010). GOS at least partly fulﬁll
similar roles as HMOs, but further information is required about the
speciﬁc mechanisms of GOS utilization. Previously we reported that a
subset of branched GOS mimic HMOs in the activation of bacterial
mucin utilization pathways, which may allow bacterial species to ad-
here to the mucosal layer and colonize the GI tract (Lammerts et al.,
2017). A second mechanism involves direct use of GOS as a nutritional
source by colonic bacteria; GOS has been shown to activate galactan/
galactose utilization systems in Biﬁdobacterium and Bacteroides
(Lammerts et al., 2017). One particular enzyme from the galactan uti-
lization system identiﬁed as important for GOS utilization by gut bac-
teria is an extracellular endo-galactanase from the GH53 family as de-
scribed in the CAZy database (www.cazy.org) (Lombard et al., 2014).
Coincidently, several probiotic biﬁdobacteria and prominent colonic
commensal bacterial species that beneﬁt from HMOs for growth also
harbor galactan utilization systems and GH53 enzymes (Lammerts
et al., 2017; O'Connell Motherway et al., 2013). Recently Thongaram
et al. 2017 reported that GOS utilization in lactobacilli, another group
of probiotic bacteria with relevance for a healthy (infant) gut, poorly
use GOS with higher DP. They are able to grow on lactose, however,
involving a dedicated uptake system and an intracellular β-galactosi-
dase. As allochthonous members of the human colon microbiota, they
may instead beneﬁt from GOS breakdown products generated by other
autochthonous members (Walter, 2008).
As a proven prebiotic, beneﬁcial eﬀects of GOS may also occur
through application in synbiotics. In such synergistic synbiotics the
prebiotic is supplied as a speciﬁc growth substrate for the cognate
probiotic bacterium (Kolida and Gibson, 2011). Some studies already
have reported the use of GOS in synbiotics, i.e. in combination with a
given probiotic strain, but often the synergistic eﬀect of the combina-
tion remains to be proven (Krumbeck et al., 2018; Macfarlane et al.,
2007).
In earlier work we have identiﬁed an extracellular GH53 enzyme
from B. thetaiotaomicron that is implicated in both pectic galactan and
prebiotic GOS utilization and releases galactobiose and galactose as
ﬁnal products of pectic galactan degradation (Lammerts et al., 2017). In
the present study, we further characterized this endo-galactanase en-
zyme in terms of three-dimensional structure and enzymatic activity, in
order to further understand its role in GOS degradation. We observed
that this enzyme degrades β-1,4-galactan (potato galactan) but not β-
1,3-galactan (as found in larch wood arabinogalactan). Its three-
dimensional crystal structure revealed that BTGH53 is similar to fungal
GH53s rather than to the bacterial GH53 enzyme characterized from
Bacillus licheniformis (Le Nours et al., 2003; Ryttersgaard et al., 2002).
Speciﬁcally, BTGH53 shows a diﬀerent organization of βα-loops 6, 7
and 8 lacking additional substrate binding sites which is not observed
for the Bc. licheniformis GH53 enzyme, along with an additional D331
residue in BTGH53 which stabilizes the axial C4 hydroxyl group of
galactose in the −1 subsite position. As a result BTGH53 is able to
degrade shorter GOS and pNP-galactose. Finally, we demonstrate that
in the presence of BTGH53 probiotic Lactobacillus strains become fully
competent to degrade and grow on larger DP GOS. These results show
in more detail how GOS are metabolized by GH53 enzymes, and further
our understanding of how extracellular CAZymes facilitate growth of
beneﬁcial probiotic Lactobacillus strains in complex microbial environ-
ments.
2. Materials and methods
2.1. Materials
Azo-galactan and galactobiose were purchased from Megazyme
(Bray, Ireland). Puriﬁed GOS (pGOS derived from Vivinal® GOS with
glucose, galactose and lactose largely removed from the commercial
product) was provided by FrieslandCampina Domo (Amersfoort, The
Netherlands), and P5 GOS by Winclove Probiotics (Amsterdam, the
Netherlands). Composition of pGOS has been analyzed and described
previously (Lammerts et al., 2017). P5 GOS composition was analyzed
as described below. All other compounds were purchased from Sigma
(Zwijndrecht, NL). Bacteroides thetaiotaomicron VPI-5482 was pur-
chased from DSMZ (DSM 2079, ATCC 29148) (Braunschweig, Ger-
many). Lactobacillus paracasei W20, Lactobacillus casei W56 and Lacto-
bacillus salivarius W57 were a kind gift from Winclove Probiotics
(Amsterdam, NL). Crystallization materials were purchased from Mo-
lecular Dimensions (Newmarket, UK).
2.2. B. thetaiotaomicron growth experiments
B. thetaiotaomicron growth was carried out as described previously
(Lammerts et al, 2017). Brieﬂy, overnight cultures of B. thetaiotaomicron
were grown at 37 °C in rich medium (Brain Heart infusion
broth+5mM L-cysteine under anaerobic conditions in an anaerobic jar
(Oxoid) with a GasPak (BD). The following day, 1ml of a 50-fold di-
lution of a B. thetaiotaomicron overnight culture was used to inoculate
carbon-limited minimally deﬁned medium with 100mM KH2PO4 (pH
7.2), 15mM NaCl, 8.5mM (NH4)2SO4, 4mM L-cysteine, 1.9mM he-
matin, 200mM L-histidine, 100 nM MgCl2, 1.4 nM FeSO4·7H2O, 50mM
CaCl2, 1 mgml−1 vitamin K3, 5 ngml−1 vitamin B12 and individual
carbon sources (0.5%, wt vol−1). Culture tubes containing 2ml total
volume were prepared in Hungate tubes under anaerobic conditions
using Hungate techniques under 100% CO2 gas (Daniels and Zeikus,
1975). Growth curves were obtained by incubating tubes at 37 °C and
taking optical density readings at 600 nm (OD600) at ∼1–2 h time
intervals over a 4 day period.
2.3. Protein production, crystallization, data collection and structure
determination
Production and puriﬁcation of BTGH53 protein was carried out as
described previously (Lammerts et al., 2017). Further puriﬁcation steps
were used to obtain fully puriﬁed BTGH53 protein for crystallization
experiments. Size exclusion chromatography was performed using Se-
phadex S75 in buﬀer containing 20mM Tris pH 7.5, 150mM NaCl.
Fractions containing the puriﬁed protein were pooled and concentrated
using an Amicon centricon ﬁlter (Millipore) with a 10 KDa MWCO
membrane.
Crystallization trials were performed at room temperature using the
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sitting-drop vapor diﬀusion method using commercially available
crystallization screens. MRC2 Plates were setup by pipetting 100 nL;
10mg/ml protein and 100 nL screen condition together using a
Mosquito pipetting robot (TTP Labtech Ltd). Crystals were found after a
few days up to several weeks at various conditions. Crystals from
condition 20% PEG6000, 200mM NH4Cl, MES pH 6.0 (Wizard Classic 3
& 4 screen, Rigaku) were recognized as most promising single crystals
based on size (approximately 185×80×80 µm) and sharp edges. For
determination of the apo protein structure the crystal was transferred in
a new drop with a higher PEG6000 concentration of 22% to reach cryo
conditions, and directly ﬂash frozen in a stream of nitrogen gas at
110 K. Diﬀraction data was collected at 110 K using a Microstar rotating
anode (Cu) X-ray source (Bruker AXS GmbH) in combination with
Helios optics (Incoatec GmbH) and a MAR345dtb detector
(Marresearch GmbH). Diﬀraction images for 130° were recorded with
1° oscillation.
For determination of the galactose bound protein structure, the
crystal was transferred to a new drop for 30 s containing a reservoir
solution with 50mM pGOS and ﬂash frozen in liquid nitrogen. The data
collection was performed under cryo conditions at the P13 EMBL
Beamline (Hamburg, Germany). Diﬀraction images for 135° were re-
corded with 0.05° oscillations.
Diﬀraction images were indexed, integrated, scaled and merged
with programs XDS and Aimless (Kabsch, 2010). The structure of the
apo BTGH53 protein was determined by the molecular replacement
method using Phaser (McCoy et al., 2007) where four homology search
models were used. These search models were obtained from the FFAS
server blast and the top four score structural homologues (PDB codes:
1FHL; 1HJQ; 4BF7; 1HJS) with 28–31% sequence identity were used to
build homology models using the SCWRL modelling method in the
mixed atom mode by replacing template residues with serine for un-
conserved residues between the target and the template except for
glycines and alanines (Jaroszewski et al., 2011; Krivov et al., 2009).
After Phaser, building the ﬁnal model was performed with the ARP/
wARP program and reﬁnement was done with Refmac5, both from the
CCP4 software suite (CP Collaborative, 1994; Winn et al., 2011). For
the crystals used in the substrate soak experiment the search co-
ordinates from the apo structure were used.
Crystals belonging to space group P21 contained 2 protein molecules
in the asymmetric unit having a solvent content of 39.1%. A summary
of the data collection statistics is given in Table 1 and of the reﬁnement
statistics in Table 2.
2.4. Determination of BTGH53 speciﬁc activities
The activity of BTGH53 on the synthetic substrate pNP-galactose
was determined by measuring the release of 4-nitrophenol at 405 nm.
Assays were run using diﬀerent buﬀers over a range of pH values:
50mM sodium acetate pH 5.5, 6.0; 50mM sodium phosphate pH 6.0,
6.5, 7.0; 20mM HEPES pH 7.5; 20mM Tris pH 7.5, 8.0. The molar
extinction coeﬃcients used to calculate pNP release were
2.31mM−1 cm−1 (pH 5.5), 3.66mM−1 cm−1 (pH 6.0),
7.38mM−1 cm−1 (pH 6.5), 11.39mM−1 cm−1 (pH 7.0),
14.22mM−1 cm−1 (pH 7.45), 17.26mM−1 cm−1 (pH 8.0). Reactions
were initiated by the addition of BTGH53 to a ﬁnal concentration of
5 µM. Reaction rates were plotted against pH producing a bell shaped
curve. Optimum pH conditions were found to be 50mM phosphate
buﬀer pH 7.0 which was used for all subsequent studies.
Enzyme activity was measured with 0.1–15mM pNP-galactose in
50mM phosphate buﬀer pH 7.0 using the conditions described above.
Reaction rates were monitored continuously at 405 nm for 600 s, the
rates were taken as the slope between 300 and 360 s. The data were
ﬁtted to the Michaelis-Menten equation in GRAFIT which was used to
calculate the KM and Vmax values. The Vmax was adjusted for the enzyme
concentration to give the kcat value.
BTGH53 endo-galactanase speciﬁc activity was determined using
the dyed substrate Azo-galactan according to manufacturer’s instruc-
tions. A reaction mixture containing 500 µl 2% Azo-galactan in 50mM
phosphate buﬀer pH 7.0 plus 500 µl of 5 µM BTGH53 in the same buﬀer
was incubated for 10min at 37 °C. After incubation, the reaction was
stopped and the residual high molecular weight polymer was pre-
cipitated by the addition of 2.5 ml of cold 100% ethanol. The reaction
mixture was centrifuged for 10min at 2800g and the produced low-
molecular weight dyed fragments in the supernatant assayed by mea-
suring absorbance at 590 nm. Units of enzyme activity were calculated
from absorbance values by using a standard curve supplied by the
manufacturer that standardized values of absorbance at 590 nm to
amount of reducing sugar ends formed obtained according to the
method Nelson/Somogyi (Somogyi, 1952). One unit of activity (GalU/
mg) was deﬁned as the amount of enzyme required to release 1 μmol of
galactose reducing sugar equivalents from galactan per min.
2.5. Lactobacillus growth curves
Lactobacillus growth curves were measured in microtiter plates as
described previously (Boger et al., 2018). In brief, Lactobacillus strains
were grown in modiﬁed MRS medium containing 5mgml−1 GOS.
BTGH53 treated GOS was prepared by incubating 10mgml−1 GOS
with 200 µM BTGH53 in 50mM sodium phosphate buﬀer pH 7.0 at
37 °C for 24 h. After digestion, BTGH53 was inactivated by heat
Table 1
Data collection & statistics. Between brackets: Statistics highest resolution shell.








Wavelength (Å) 1.54 0.98
Space group P21 P21
mol/A.U 2 2
Solvent content (%) 39.11% 41.24
Unit-cell parameters
a, b, c (Å) 47.2, 44.7, 137.6 47.5, 45.6, 138.8
α, β, γ (°) 90.0, 99.4, 90.0 90.0, 99.8, 90.0
Resolution range high
(Å)
1.93 (1.98–1.93) 1.79 (1.83–1.79)
Resolution range low (Å) 46.58 46.85
Rmerge 0.073 (0.324) 0.110 (0.403)
Rp.i.m 0.053 (0.247) 0.085 (0.328)
Total No. of observations 110,321 (5637) 138,347 (6516)
Total No. of unique
reﬂections
40,545 (2339) 53,053 (2687)
Mean I/σ (I) 14.06 (3.28) 8.6 (2.8)
Completeness (%) 94.8 (81.1) 96.1 (80.5)







Resolution (Å) 1.93 1.79
R 0.1735 0.170
Rfree 0.2247 0.220
RMSD from target geometry
Bond lengths (Å) 0.010 0.0115
Bond angels (°) 1.356 1.4558
Tot. number of atoms 5369 5678





Favoured (%) 96 97
Allowed (%) 4 3
Outliers (%) 0 0
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treatment (10min at 80 °C), any precipitant removed by centrifugation
(5min, 16,000g) and samples were ﬁlter sterilized using 0.2 μm cellu-
lose acetate ﬁlters. After Lactobacillus growth, culture supernatants
were analyzed for any remaining GOS molecules using high pressure
anion exchange chromatography with pulsed amperometric detection
(HPAEC-PAD) as previously described (Lammerts et al., 2017).
2.6. Analysis of GOS composition
P5 GOS was analyzed using comparative HPAEC-PAD with known
structural components (covering>99% of the substrate composition)
of Vivinal® GOS as reference (van Leeuwen et al., 2016). In brief, P5
GOS was dissolved to 1mg/ml in 80% (vol vol−1) dimethyl sulfoxide
and its composition analyzed on a Dionex DX500 work station equipped
with an ED40 pulsed amperometric detection system (HPAEC-PAD).
Components were separated on a CarboPac PA-1 column (250 by 5mm;
Dionex) using a system of buﬀer A= 0.1M NaOH, buﬀer B=0.6M
NaOAc in 0.1M NaOH, buﬀer C=deionized water and buﬀer
D=50mM NaOAc. Separation was carried out with 10% A, 85% C and
5% D in 25min to 40% A, 10% C and 50% D, followed by a 35-min
gradient to 75% A, 25% B, directly followed by 5min washing with
100% B and reconditioning with 10% A, 85% B and 5% D for 7min.
Furthermore, P5 GOS was subjected to NMR spectroscopy and known
structural-reporter group signals used to evaluate the 1H NMR spectrum
of P5 GOS as described by Yin et al. (2017). Brieﬂy, P5 GOS was lyo-
philized and exchanged twice with 99.9% atom D2O (Cambridge Iso-
tope Laboratories Ltd, Andover, MA). Then, the sample was dissolved in
650 μl 99.9% atom D2O, containing 25 ppm acetone as internal stan-
dard. The 1D 1H NMR spectra were recorded at a probe temperature of
298 K in a Varian Inova 600 spectrometer (NMR department, University
of Groningen, The Netherlands).
2.7. Protein data bank accession codes
Structures of BTGH53 were deposited at PDB with the codes PDB ID
6GP5 (Apo BTGH53) and 6GPA (BTGH53+Galactose).
3. Results and discussion
3.1. BTGH53 is speciﬁc for β-1,4-galactans
We previously reported that BTGH53 is important for degradation
of GOS by B. thetaiotaomicron and that the enzyme is speciﬁc for β-1,4-
linked galactans (pectic galactan) and not for the β-1,3-linkage type as
found in larch wood arabinogalactans (Lammerts et al., 2017). In the
present study BTGH53 was further characterized, both structurally and
enzymatically. First, the speciﬁc activity of BTGH53 on high molecular
weight galactan was determined using the Azo-galactan colorimetric
substrate (derived from potato galactan). BTGH53 speciﬁc activity with
Azo-galactan was as 105.8 ± 0.9 GalU/mg, which is a 10-fold diﬀer-
ence lower to the other characterized GH53 enzymes (Ryttersgaard
et al., 2004). Previously, we observed that also signiﬁcant levels of
galactose were formed after BTGH53 activity on galactan, similar to
what was observed for fungal GH53 enzymes (Lammerts et al., 2017).
Therefore exo-activity of BTGH53 was tested with the chromogenic
substrate 4-nitrophenyl-β-D-galactopyranoside (pNPG). This indeed re-
sulted in yellow color formation due to the release of 4-nitrophenyl,
with a pH optimum at pH 7.0 (not shown). BTGH53 displayed Mi-
chaelis-Menten kinetics, with a KM value of 69.7 ± 5.7 µM and a kcat
value of 29.6 ± 0.9 s−1 (kcat/KM value is 425mM−1 s−1). The mod-
erate turnover rate of BTGH53 on the pNPG substrate is similar to that
observed for the fungal GH53 enzymes AAGAL and MGGAL
(Torpenholt et al., 2011). Hydrolysis decreased above concentrations of
15mM pNPG which may be due to transglycosylation activity of
BTGH53, as was also suggested for the fungal GH53 enzymes. BTGH53
was inactive on lactose and galactobiose (mixture of β-D-Galp-(1→ 3)-D-
Gal plus β-D-Galp-(1→ 4)-D-Gal) but able to cleave DP3 GOS (Lammerts
et al., 2017). The ability of BTGH53 to hydrolyze galactose from pNPG
and to cleave DP3 GOS, makes this enzyme more similar to the fungal
GH53 endo-galactanases than to the bacterial BLGAL enzyme from Bc.
licheniformis.
3.2. Structure of BTGH53
In order to gain further insights into the catalytic mechanism of
BTGH53, we determined the three-dimensional structure of BTGH53.
Native crystals were soaked in 50mM pGOS in order to get a high re-
solution structure of BTGH53 in complex with products. We obtained a
high resolution data set (1.79 Å) and solved the structure by molecular
replacement as described (see Methods). The ﬁnal model of BTGH53
consisted of amino acid residues 37–350 with two molecules in the
asymmetric unit. Each BTGH53 molecule contained one galactose re-
sidue in the active site. The high resolution model was reﬁned to give
an overall R/Rfree of 0.17/0.22.
The overall fold and architecture of BTGH53 is similar to the other
structurally characterized bacterial GH53 enzyme, BLGAL from Bc. li-
cheniformis (PDB code 1UR4) (core RMSD 1.48 Å, 32.5% sequence
identity) and the closely related fungal AAGAL enzyme of Aspergillus
aculeatus (PDB code 1FHL, core RMSD 1.49 Å, 29.5% sequence identity)
(Fig. 1). The closest structure for the bacterial homologue Bc. licheni-
formis 1UR4 (based on sequence identity) did not work for ﬁnding the
phases for the BTGH53 structure. An alternative approach to solving the
BTGH53 structure was then attempted using the FFAS blast algorithm
(http://ﬀas.sanfordburnham.org/ﬀas-cgi/cgi/ﬀas.pl) to obtain the clo-
sest structural homologues based on fold and function (Jaroszewski
et al., 2011). The top 4 from the FFSA search (PDB codes 4BF7, 1FHL,
1HJS and 1HJQ) were used for ﬁnding the phases.
BTGH53 exhibits a (βα)8 TIM barrel fold with the catalytic ma-
chinery positioned within the center of the barrel (Fig. 1). The candi-
date catalytic residues are D132 as acid/base and E180 as nucleophile,
based on the position of these catalytic residues within all GH53 en-
zymes which belong to clan GH-A (CAZy database GH53 https://www.
Fig. 1. 3-Dimensional structure of the BTGH53 enzyme in complex with a ga-
lactose molecule (orange) showing the organization of a (βα)8-barrel. Residues
highlighted in pink are the catalytic residues D132 and E180, and stabilizing
residue W130.
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cazypedia.org/index.php/Glycoside_Hydrolase_Family_53; Lombard
et al., 2014). These residues align with the catalytic residues D117 and
E165 of the GH53 enzyme from Bc. licheniformis (PDB code 1UR4).
In one of the protein molecules in the asymmetric unit, the galactose
molecule occupying the −1 subsite was stabilized by direct hydrogen
bonding with D331 to its C4 and C6 hydroxyl groups, while W130 fa-
cilitated stacking interactions with the galactose molecule (Fig. 2A). In
the other protein molecule in the asymmetric unit, we observed that
D331 is rotated 180° about Cb and does not form hydrogen bonds with
galactose occupying the −1 subsite (Fig. 2B). Therefore we speculate
that D331 plays an important role in forming the−2 subsite, where in
the presence of galactobiose, the −2 galactose is stabilized by D331,
while in its absence, D331 forms hydrogen bonds with galactose in−1.
This explains why BTGH53 is active on pNP-galactose.
BTGH53 lacks a large loop region within the substrate binding site
which is present in BLGAL (Fig. 2C–E). In BLGAL an extended loop 8
from the beta strand at position 8 forms a substrate binding site region
with the −3 and −4 substrate binding subsites. The loop 8 region in
BLGAL restricts this enzyme from cleaving GOS smaller than DP4
(Ryttersgaard et al., 2004). With the loop 8 region missing in BTGH53,
Fig. 2. Structural characteristics original to BTGH53. (A+B) 2Fo-Fc omit electron density maps for the original unreﬁned density, contoured to 1σ, showing the
bound galactose. D331 is proposed to play an important role in forming the−2 subsite and we speculate its ﬂexibility, as indicated by the diﬀerent positions within
the individual protein molecules in the asymmetric unit, provides BTGH53 the ability to cleave shorter galactooligosaccharide substrates. (A) protein 1 active site
showing hydrogen bonds between D331 and C4 and C6 OH groups, (B) protein 2 active site where D331 is rotated 180° about Cβ with respect to protein A. Amino
acids are indicated in grey, galactose molecules are indicated in green, D331 highlighted in blue oval. (C) Amino acid sequence alignment of BTGH53 and BLGAL
(PDB code 1R8L) showing the missing loop 8 region in BTGH53; βα-loops numbered according to the structure of BLGAL (Ryttersgaard et al., 2004). Loop 8 is
highlighted in light blue in BLGAL (residues 328–378; missing in BTGH53); alignment prepared with ClustalOmega and ESPript (McWilliam et al., 2013; Robert and
Gouet, 2014). (D) 3-dimensional organization of the active sites of BLGAL (bound with galactobiose in orange) and (E) BTGH53 (bound with galactose in orange).
Catalytic residues of BLGAL (D117 and E165) and corresponding residues D132 and E180 in BTGH53 are shown. Loop 8 region lacking in BTGH53 is highlighted by
the (empty) blue circle.
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the enzyme is able to bind to and act upon smaller substrates, such as
galactotriose, producing galactobiose and galactose (Lammerts et al.,
2017). This activity makes BTGH53 much more similar to the fungal
GH53 enzyme AAGAL (Ryttersgaard et al., 2002).
Due to a truncated loop 8, BTGH53 loop 7 is not linked to loop 8,
which is important for active site stability in all other structurally
characterized GH53 enzymes (Ryttersgaard et al., 2004). In both
AAGAL and BLGAL, loops 7 and 8 are linked via coordination of a
calcium ion (BLGAL) or via a disulﬁde bond (AAGAL). In all fungal
GH53 enzymes, the cysteine residues involved in disulﬁde bond for-
mation are conserved (Le Nours et al., 2003). To correct for this,
BTGH53 also has a truncated loop 7 region creating a large gap which is
ﬁlled by an extended loop 6 region. This loop 6 region forms part of the
BTGH53 active site. This organization has not been observed in any
other GH53 structures studied to date. These structural changes in loops
6, 7 and 8 in BTGH53 may have clear eﬀects on its activity and spe-
ciﬁcity. BTGH53 is active on β-1,4-linked galactan but not on larch
arabinogalactan which is primarily β-1,3-galactan (Megazyme Larch
Wood arabinogalactan, product code P-ARGAL). The structural changes
observed in the substrate binding site of BTGH53 thus may select for
only the β-1,4-linkage type and accommodate molecules of shorter DP
length as observed previously (Lammerts et al., 2017).
The acid/base D132 residue forms a hydrogen bond with the ga-
lactose C2 hydroxyl group, where the E180 carboxyl group can perform
nucleophilic attack on C1. Because of the loop 8 truncation in BTGH53,
an important W363 residue (Fig. 2D) which forms stacking interactions
with the galactose in the BLGAL −2 subsite is missing in the BTGH53
structure which may explain why we did not observe a second galactose
molecule in the BTGH53 active site (Fig. 2D+E).
A total of ﬁve GH53 structures (http://www.cazy.org/GH53_
structure.html) have been solved to date, four from eukaryotic soil
fungi and one from a soil bacterium. BTGH53 is the second bacterial
GH53 enzyme whose structure has been solved, the ﬁrst from a bac-
terium that resides in the human gastrointestinal tract. The particular
niche environment where a microbe resides may inﬂuence how its
enzymes evolve also with respect to substrate speciﬁcity. B. thetaio-
taomicron is resident in the distal gut, and the extracellular BTGH53
may target non-digestible GOS that reach the distal gut. The observed
Fig. 3. HPAEC-PAD analysis of 1mgml−1 pGOS (A) and P5 GOS (B) untreated (grey) and after incubation with BTGH53 (black). Adjacent tables show degree of
polymerization of GOS components of corresponding peaks. Peak numbers with increased peak height due to BTGH53 activity are highlighted in bold, underlined
peak numbers refer to compounds recalcitrant to BTGH53.
Fig. 4. Structural identity of GOS compounds comprising the DP2 fraction. 3 β-
D-Galp-(1→ 6)-D-Gal, 4 β-D-Galp-(1→ 6)-D-Glc (allolactose), 5 β-D-Galp-(1→ 4)-
D-Glc (lactose), 7 β-D-Galp-(1→ 4)-D-Gal (galactobiose), 8a β-D-Galp-(1→ 2)-D-
Glc, 8b β-D-Galp-(1→ 3)-D-Glc. Numbers indicate HPAEC-PAD chromatogram
peaks shown in Fig. 3.
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changes to the BTGH53 active site thus may allow B. thetaiotaomicron to
eﬃciently degrade galactan compounds of the β-1,4-linkage type down
to its smallest constituents. The B. thetaiotaomicron galactan utilization
system is part of a higher order system that allows degradation of all
pectin components with a backbone of β-1,4-galactan, such as rham-
nogalacturonans (Ndeh et al., 2017). Only exposure to pectic galactan,
and not arabinogalactan of the β-1,3-linkage type (such as larch wood),
upregulates the expression of this system and its BTGH53 enzyme. The
structural similarity of higher DP GOS to pectic galactan also activates
the expression of BTGH53. Therefore the production of the GH53 en-
zyme is a feature associated with eﬃcient GOS utilization in B. the-
taiotaomicron.
3.3. Eﬀects of BTGH53 activity on growth of probiotic lactobacilli
Lactobacilli constitute probiotic bacterial strains that very speciﬁ-
cally utilize GOS with a degree of polymerization ≤2 (Thongaram
et al., 2017). Pure cultures of Lactobacillus strains tested hardly con-
sumed prebiotic GOS and thus were unable to grow with GOS as carbon
sources. Therefore we subsequently tested whether treatment of GOS
with BTGH53 activity actually stimulated growth of probiotic lacto-
bacilli on GOS mixtures.
Two commercial GOS preparations were used, pGOS and P5 GOS.
Their composition was analyzed recently using HPAEC-PAD and NMR
spectroscopy to elucidate structural identity of nearly all their compo-
nents (40 and 26, respectively) (van Leeuwen et al., 2014, 2016; Figs.
S1 and S2). In brief, in pGOS we identiﬁed a total of 40 compounds with
diﬀerent degrees of polymerization (DP) (mostly DP 3–6) and/or
glycosidic linkages (Fig. 3A). Its major component by peak height in the
HPAEC-PAD chromatogram was the trisaccharide 4′-galactosyllactose
(peak 11, Fig. 3A). Also DP4 compounds, linear and branched, con-
stituted a major fraction of pGOS (28% of total GOS mixture). Com-
parative HPAEC-PAD analysis of pGOS and P5 GOS, followed by NMR
analysis of P5 GOS, also allowed elucidation of the P5 GOS structures
(Figs. S1 and S2). All 26 GOS structures found in P5 GOS were also
found in pGOS, but in clearly diﬀerent ratios (Fig. 3B). The two major
components were DP3 4′-galactosyllactose (as in pGOS) and the cor-
responding elongated product DP4 β-D-Galp-(1→ 4)-β-D-Galp-(1→ 4)-
β-D-Galp-(1→ 4)-D-Glc (Fig. 3B). Together these two linear DP3 and
DP4 components constituted up to 44% of total GOS composition in P5
GOS (24% in pGOS). P5 GOS and pGOS diﬀered at the level of branched
DP3 and DP4 components. Compounds eluting as peak 10 and 16 were
nearly absent in P5 GOS (7% and 5% in pGOS) (Figs. 3B and S1). Also
compounds with DP5 and larger were reduced in P5 GOS (5%) in
comparison to pGOS (10%). Interestingly, two compounds from the
DP2 pool clearly found in pGOS were absent in P5 GOS, allolactose β-D-
Galp-(1→ 6)-D-Glc and β-D-Galp-(1→ 6)-D-Gal (Fig. 4). Finally, lactose
was still present in P5 GOS (13%) which was removed in pGOS.
Growth of probiotic lactobacilli with pGOS and P5 GOS yielded OD
600 nm values at stationary phase between 19 and 63% of positive
controls (with glucose) (Table 3). Final OD values for L. paracasei W20
and L. casei W56 were clearly lower for pGOS than for P5 GOS (Fig. 5).
In contrast, L. salivarius W57 reached similar OD values with both GOS
preparations (0.53 with P5 GOS and 0.49 with pGOS). The results re-
ﬂect speciﬁc GOS utilization preferences of these lactobacilli. HPAEC-
PAD analysis of the bacterial culture supernatants at stationary phase
Table 3
Growth of Lactobacillus strains on 5mgml−1 GOS and GOS pre-incubated with BTGH53. No exponential growth phase was detected for L. paracasei W20 on pGOS.
OD600 nm values obtained at stationary growth phase are expressed relative to corresponding OD600 nm values of glucose controls set as 1. All values shown are
means of n=3 biological replicates. n.a., not applicable.
Relative OD600 at stationary phase (16 h)
P5 GOS P5 GOS+BTGH53 pGOS pGOS+BTGH53
L. salivarius W57 0.46 ± 0.01 0.97 ± 0.01 0.41 ± 0.02 0.99 ± 0.03
L. paracasei W20 0.47 ± 0.01 0.99 ± 0.02 0.19 ± 0.02 0.86 ± 0
L. casei W56 0.63 ± 0 0.93 ± 0 0.47 ± 0 0.88 ± 0
Growth rates (h−1)
P5 GOS P5 GOS+BTGH53 pGOS pGOS+BTGH53
L. salivarius W57 0.27 ± 0.01 0.37 ± 0 0.21 ± 0 0.38 ± 0.02
L. paracasei W20 0.07 ± 0 0.18 ± 0 n.a. 0.16 ± 0
L. casei W56 0.10 ± 0 0.20 ± 0 0.07 ± 0 0.2 ± 0
Fig. 5. Anaerobic growth of L. paracasei W20 (A), L. salivarius W57 (B), L. casei W56 (C) with 5mgml−1 pGOS and P5 GOS, pure and (*) BTGH53 digested. Glucose
(5mgml−1) served as positive control. In some cases error bars are smaller than symbols and therefore not apparent.
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showed that these lactobacilli diﬀer most clearly in utilization of the
various DP2-DP3 GOS. L. salivariusW57 consumed any DP2 GOS (peaks
3–8, Fig. 6) present in both GOS and additionally the DP3 GOS com-
ponent β-D-Galp-(1→ 2)-[β-D-Galp-(1→ 4)-]D-Glc (peak 9, Fig. 6). L.
casei W56 speciﬁcally utilized the DP2 components and L. paracasei
W20 any DP2 component, but not allolactose (Fig. 6). Similar to L.
paracasei W20, (Thongaram et al., 2017) recently identiﬁed L. paracasei
LCV-1 as strong utilizer of lactose and a GOS substrate comprising 59%
DP2 GOS.
When incubating the two commercial GOS with BTGH53, compo-
sition shifted from DP3-DP4 size dominating in untreated GOS to DP2
components in BTGH53 treated GOS. Galactobiose (peak 7, Fig. 3)
became the dominating component released to similar levels by
BTGH53 treatment. In BTGH53 treated pGOS also the DP2 components
β-D-Galp-(1→ 2)-D-Glc, β-D-Galp-(1→ 3)-D-Glc (peaks 8a and 8b, see
Figs. 3 and 4) increased, but they remained nearly the same in BTGH53
treated P5 GOS. Besides galactobiose, lactose was the second major
component in BTGH53 treated P5 GOS, whereas in BTGH53 treated
pGOS the peak heights of lactose and other DP2 components were more
equally distributed. Analysis of pGOS products after BTGH53 treatment
showed that it was inactive on DP3 branched GOS, the linear DP3
component 6′-galactosyllactose and the DP2 units β-D-Galp-(1→ 2)-D-
Fig. 6. Utilization of GOS components by probiotic Lactobacillus strains analyzed by HPAEC-PAD. Proﬁles of pGOS and P5 GOS shown in grey (control). Composition
of the two GOS preparations in bacterial culture supernatants harvested at stationary growth phase (s. Fig. 5) are shown in black (untreated GOS) and blue (BTGH53
treated GOS). Any GOS components not utilized by probiotic strains in untreated GOS are numbered according to Fig. 3. Peaks arising from medium (mMRS)
components are indicated with *.
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Glc, β-D-Galp-(1→ 3)-D-Glc, β-D-Galp-(1→ 6)-D-Gal, β-D-Galp-(1→ 6)-D-
Glc. Similar observations were made with P5 GOS. The β-D-Galp-(1→
6)-D-Gal, β-D-Galp-(1→ 6)-D-Glc compounds were absent in P5 GOS.
They also were not found in the chromatogram of BTGH53 treated P5
GOS, thus also not liberated by enzymatic activity with GOS of higher
DP. With both GOS samples BTGH53 treatment caused a signiﬁcant
increase in the DP2 compounds β-D-Galp-(1→ 2)-D-Glc, β-D-Galp-(1→
3)-D-Glc, β-D-Galp-(1→ 4)-D-Gal and β-D-Galp-(1→ 4)-D-Glc (Figs. 3 and
4). This DP2 fraction may speciﬁcally stimulate growth of probiotic
lactobacilli.
All three lactobacilli clearly beneﬁted from the BTGH53 treatment
of the GOS substrates and reached OD values at stationary phase close
to positive controls (glucose) (Fig. 5, Table 3). BTGH53 hydrolysis
products of P5 GOS stimulated the extent of growth of L. paracasei W20
better than the ones obtained from pGOS. BTGH53 treated GOS also
resulted in reduced lag phases of growth for L. paracasei W20 and L.
casei W56 (Fig. 5).
HPAEC-PAD analysis demonstrated that lactobacilli consumed a
broader range of prebiotic GOS molecules in BTGH53 treated samples
than in untreated ones. L. salivarius W57 consumed the broadest range
of GOS by utilizing any component besides the branched trisaccharides
β-D-Galp-(1→ 2)-[β-D-Galp-(1→ 6)-]D-Glc and β-D-Galp-(1→ 3)-[β-D-
Galp-(1→ 4)-]D-Glc (peak 10, Fig. 6). These two components were also
not used by L. caseiW56 and L. paracaseiW20 and in addition these two
strains didn’t consume β-D-Galp-(1→ 2)-[β-D-Galp-(1→ 4)-]D-Glc (peak
9, Fig. 6) which was also observed with untreated samples. These re-
maining compounds weren’t cleaved by BTGH53 in enzymatic diges-
tions of GOS mixtures (Fig. 3). Overall, pre-treating GOS mixtures with
BTGH53 enabled the strains to beneﬁt from a much broader range of
GOS molecules with higher DP (Fig. 6).
4. Conclusions
In this paper we have characterized the B. thetaiotaomicron BTGH53
β-1,4-galactanase in structural and functional detail. The data shows
that BTGH53 activity on prebiotic GOS mixtures results in an increase
of DP2 GOS with clear stimulatory eﬀects on growth of lactobacilli. B.
thetaiotaomicron is a dominant inhabitant of the human colon and
probiotic lactobacilli are known to be present in the same compartment
(Alander et al., 1999; Saremdamerdji et al., 1995), with potential cross-
feeding eﬀects in vivo. Similar stimulatory eﬀects may be exerted by
extracellular GH53 enzymes from other colon bacteria, but this also
depends on their GOS product spectra. The Biﬁdobacterium breve galA
gene for instance encodes an extracellular GH53 enzyme (O'Connell
Motherway et al., 2013). GalA is an endo-acting galactanase that re-
leases galactotriose as major product instead of galactobiose. Our study
shows that lactobacilli are very speciﬁc for DP2 GOS utilization and
thus will not beneﬁt from products of GalA activity.
Second, our results show that addition of BTGH53 to preparations of
probiotic lactobacilli and prebiotic GOS mixtures provides a synbiotic
combination: GOS DP2 products released by BTGH53 from longer GOS
DP speciﬁcally can be utilized for growth by lactobacilli. Such synbiotic
combinations may be prepared either by adding (puriﬁed) carbohy-
drate-active enzymes or by pairing probiotic bacteria that (mutually)
beneﬁt from each other by producing complementary enzymes on a
particular prebiotic substrate.
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